Investor relations
4 Reasons to invest in Bio-Works
An investment in Bio-Works allows participation in the expansive biotechnology sector but with a lower risk profile.
Bio-Works generates revenue in the early phases of a biotherapeutics’ development, long before the approval of the drug substance.
There is a strong market demand for suppliers of chromatography resins who can offer alternatives to the few that have dominated the market for decades.
Bio-Works has the foundational cornerstones in place and is well-positioned for expansive growth without large investments in the near future.
| Financial calendar | |
|---|---|
| 2026-05-13 | Quarterly report Jan – Mar 2026 |
| 2026-06-04 | Annual General Meeting for 2026 |
| 2026-08-21 | Quarterly report Apr – Jun 2026 |
| 2026-11-06 | Quarterly report Jul – Sep 2026 |
| 2027-02-19 | Year-end report Jan – Dec 2026 |
Shortcuts
Contact – Investor relations
Investor relations
Arne Hauge
Chief Financial Officer, Bio-Works Technologies
Phone: +46(0)8-502 705 83
Email: [email protected]
Stock Information
Bio-Works’ stock is listed on the Spotlight Stock Market where it is traded under the ticker BIOWKS. The ISIN code for the stock is SE0007387089.
See the current price for Bio-Works’ (BIOWKS) on the Spotlight Stock Market.
